1-4 of 4
interferon alpha 2
Close
Sort by
Journal Articles

A Study of Haemostatic Parameters in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Correlation with, Clinical, Laboratory, Molecular, and Treatment Characteristics

Nefeli Giannakopoulou, Marianna Politou, MD, Panagiotis Theodorou Diamantopoulos, MD PhD, Dimitris Korakakis, Maria Efstathopoulou, Theodora Kassi, Christina-Nefeli Kontandreopoulou, Katerina Zoi, PhD, Andreas Giannopoulos, BSc, MSc, Maria Dimou, Panayiotis Panayiotidis, MD PhD, Nora-Athina Viniou, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4304.
https://doi.org/10.1182/blood-2018-99-116660
Published: 2018
Journal Articles

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Trine Alma Knudsen, MD, Dennis Lund Hansen, MD, Lukas Frans Ocias, MD, Ole Weis Bjerrum, MD DMSc, Mette Brabrand, Daniel El Fassi, MD PhD, Mikael Frederiksen, MD, Lasse Kjær, PhD, Thomas Kielsgaard Kristensen, MSc, PhD, Torben A Kruse, Torben Mourits-Andersen, MD, Peter Møller, MD, Ulrik Malthe Overgaard, MD, Marianne Tang Severinsen, MD PhD, Vibe Skov, PhD, Jesper Stentoft, Professor, dr.MD, Jørn Starklint, MD, Karin de Stricker, MSc, PhD, Mads Thomassen, PhD, Thomas Stauffer Larsen, MD PhD, Hans Carl Hasselbalch, Professor, dr.MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 580.
https://doi.org/10.1182/blood-2018-99-111255
Published: 2018
Journal Articles

Tandem Cycle High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Maintenance Interferon Alpha-2 (IF) with or without Thalidomide (Thal) Is Associated with High Complete and Very Good Partial Response Rates, Improved Progression-Free, and Overall Survival.

George Somlo, MD, Dajun Qian, PhD, Firoozeh Sahebi, MD, Neil Martin Kogut, MD, Roberto Rodriguez, MD, Pablo Miguel Parker, MD, Leslie Popplewell, MD, Amrita Krishnan, MD, Joycelynne Palmer, PhD, Anthony Selwyn Stein, MD, Ricardo Spielberger, MD, Jeffrey Schriber, MD, Joseph Alvarnas, MD, Warren Chow, MD, Auayporn Nademanee, MD, Jasmine M. Zain, MD, Margaret R. O’Donnell, MD, Stephen J. Forman, MD
Journal: Blood
Blood (2006) 108 (11): 3089.
https://doi.org/10.1182/blood.V108.11.3089.3089
Published: 2006
Journal Articles

Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results.

Luigi Gugliotta, MD, S. Bulgarelli, MD, S. Asioli, MD, A. Tieghi, MD, G. Gardini, MD, E. Sabattini, MD, V. Franco, MD, E. Boveri, MD, H. M. Kvasnicka, MD, N. Vianelli, MD, A. Candoni, MD, R. Latagliata, MD, F. Passamonti, MD, S. Rupoli, MD, V. Martinelli, MD, A. Zaccaria, MD, F. Lauria, MD, E. De Biasi, MD, S. Sacchi, MD, M. Gobbi, MD, A. Tabilio, MD, E. Cacciola, MD, R. Cacciola, MD, A. Grossi, MD, P. Mazza, MD, F. Bonifazi, MD, P. Favini, F. Mandelli, MD, M. Baccarani, MD, J. Thiele, MD
Journal: Blood
Blood (2005) 106 (11): 4962.
https://doi.org/10.1182/blood.V106.11.4962.4962
Published: 2005